在阿比特龙治疗期间病情进展的前列腺癌患者中联合使用阿比特龙和放疗。
Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy.
作者信息
Detti Beatrice, D'Angelillo Rolando M, Ingrosso Gianluca, Olmetto Emanuela, Francolini Giulio, Triggiani Luca, Bruni Alessio, Borghesi Simona, Fondelli Simona, Carfagno Tommaso, Santini Roberto, Santoni Riccardo, Trodella Luca E, Livi Lorenzo
机构信息
Department of Radiation Oncology, AOU Careggi, Florence, Italy.
Department of Radiation Oncology, University Campus Bio-Medico di Roma, Rome, Italy.
出版信息
Anticancer Res. 2017 Jul;37(7):3717-3722. doi: 10.21873/anticanres.11744.
BACKGROUND/AIM: This multicenter, retrospective, 'field-practice' study investigated treatment outcomes of ongoing abiraterone therapy with the addition of radiotherapy (RT) - initiated for oligoprogression or with a palliative intent.
PATIENTS AND METHODS
Consecutive patients affected by metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate were considered if they had received RT after the initiation of abiraterone treatment.
RESULTS
A total of 32 patients were enrolled in the study. Median duration of abiraterone treatment was 13.0 months (range=3.8-40.9 months). Median duration of abiraterone treatment before RT was 5.9 months (range=0.4-40.0 months), and 7.2 months after RT (range=0.1-29.7 months). Median progression-free survival (PFS) was 12.6 months (95%CI=10.5-14.7) from the initiation of abiraterone treatment. From RT administration, PFS was 9.6 months (95%CI=6.4-12.9). Median overall survival (OS) since abiraterone initiation was 18.9 months (95%CI=4.7-33.0).
CONCLUSION
RT prolongs abiraterone treatment in mCRPC patients leading to better clinical outcomes with this molecule.
背景/目的：本多中心、回顾性“临床实践”研究调查了在阿比特龙持续治疗中加用放疗（RT）的治疗结果，放疗用于寡转移进展期或姑息治疗。
患者与方法
纳入接受醋酸阿比特龙治疗的转移性去势抵抗性前列腺癌（mCRPC）患者，条件为在阿比特龙治疗开始后接受了放疗。
结果
共32例患者纳入研究。阿比特龙治疗的中位持续时间为13.0个月（范围=3.8 - 40.9个月）。放疗前阿比特龙治疗的中位持续时间为5.9个月（范围=0.4 - 40.0个月），放疗后为7.2个月（范围=0.1 - 29.7个月）。从阿比特龙治疗开始计算，中位无进展生存期（PFS）为12.6个月（95%CI = 10.5 - 14.7）。从放疗开始计算，PFS为9.6个月（95%CI = 6.4 - 12.9）。自阿比特龙开始治疗以来的中位总生存期（OS）为18.9个月（95%CI = 4.7 - 33.0）。
结论
放疗可延长mCRPC患者的阿比特龙治疗时间，使用该药物可带来更好的临床结果。
Zotero 插件